Sarepta Therapeutics (NASDAQ:SRPT) Downgraded by BMO Capital Markets to Market Perform

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) was downgraded by equities researchers at BMO Capital Markets from an "outperform" rating to a "market perform" rating in a research report issued on Monday,Finviz reports. They currently have a $70.00 target price on the biotechnology company's stock. BMO Capital Markets' price objective would suggest a potential upside of 93.48% from the company's previous close.

SRPT has been the topic of a number of other reports. Morgan Stanley reduced their target price on shares of Sarepta Therapeutics from $182.00 to $113.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Cantor Fitzgerald dropped their price target on Sarepta Therapeutics from $163.00 to $81.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Evercore ISI downgraded Sarepta Therapeutics from an "outperform" rating to an "inline" rating and set a $50.00 price objective for the company. in a report on Thursday, May 8th. The Goldman Sachs Group dropped their target price on shares of Sarepta Therapeutics from $178.00 to $100.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, Piper Sandler lowered shares of Sarepta Therapeutics from an "overweight" rating to a "neutral" rating and set a $36.00 price target for the company. in a report on Monday. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $115.48.

Sarepta Therapeutics Price Performance

Shares of SRPT stock opened at $36.18 on Monday. The stock has a 50 day moving average price of $46.25 and a 200 day moving average price of $86.03. Sarepta Therapeutics has a 52-week low of $20.43 and a 52-week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The firm has a market capitalization of $3.56 billion, a P/E ratio of 28.94 and a beta of 0.61.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The company had revenue of $744.86 million for the quarter, compared to analysts' expectations of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The firm's revenue for the quarter was up 80.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.73 earnings per share. As a group, sell-side analysts predict that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SRPT. Charles Schwab Investment Management Inc. grew its stake in shares of Sarepta Therapeutics by 2.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company's stock worth $75,842,000 after acquiring an additional 12,000 shares in the last quarter. GAMMA Investing LLC grew its holdings in Sarepta Therapeutics by 4,682.8% during the 1st quarter. GAMMA Investing LLC now owns 40,845 shares of the biotechnology company's stock worth $2,607,000 after acquiring an additional 39,991 shares in the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at approximately $3,829,000. Allspring Global Investments Holdings LLC raised its holdings in shares of Sarepta Therapeutics by 16,717.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company's stock valued at $10,602,000 after purchasing an additional 84,926 shares in the last quarter. Finally, Van ECK Associates Corp grew its stake in shares of Sarepta Therapeutics by 24.4% during the fourth quarter. Van ECK Associates Corp now owns 84,834 shares of the biotechnology company's stock worth $10,315,000 after purchasing an additional 16,658 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.